Finance ❯Market Analysis ❯Stock Market
Stock Price Decline Corporate Governance Market Reactions Securities Fraud Class Action Lawsuits Whistleblower Programs Legal Recourse
The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.
